Table 3 Characteristics of patients with EOCC in the left-side and transverse-sided groups

Characteristic

Left

Transverse

P-value

n

3035

573

Sex

0.002^*

 Female

1587(52.3%)

260 (45.4%)

 Male

1448(47.7%)

313 (54.6%)

Histology

 < 0.001^*

 Non-specific adenocarcinoma

2847 (93.8%)

484 (84.5%)

 Specific adenocarcinoma

184 (6.1%)

86 (15.0%)

 Others

4 (0.1%)

3 (0.5%)

Pathologic stage

 < 0.001^*

 Stage I-II

1105 (36.4%)

260 (45.4%)

 Stage III-IV

1930 (63.6%)

313 (63.6%)

Surgery of Primary Site

0.453

 Yes

2985 (98.4%)

566 (98.8%)

 No

50 (1.6%)

7 (1.2%)

Reginal lymph node dissection

0.195

 Yes

2904 (95.7%)

555 (96.9%)

 No

131 (4.3%)

18 (3.1%)

Radiation

0.006^*

 Yes

122 (4.0%)

4 (0.7%)

 No

2913 (96.0%))

569 (99.3%)

Chemotherapy

0.013^*

 Yes

2053(67.6%)

357 (62.3%)

 No/unknown

982 (32.4%)

216 (37.7%)

Bone metastasis

0.767

 Yes

18 (0.6%)

4 (0.7%)

 No

3017 (99.4%)

569 (99.3%)

Liver metastasis

0.074^*

 Yes

561 (18.5%)

88 (15.4%)

 No

2474 (81.5%)

485 (84.6%)

Brain metastasis

0.331

 Yes

5 (0.2%)

0 (0%.0)

 No

3030 (99.8%)

573 (100.0%)

Lung metastasis

0.030^*

 Yes

106 (3.5%)

10 (1.7%)

 No

2929 (96.5%)

563 (98.3%)

Grade

 < 0.001^*

 Well and moderate

2564 (84.5%)

446 (77.8%)

 Poor

471 (15.5%)

127 (22.2%)

Pretreatment CEA level

0.532

 Negative

1743 (57.4%)

321 (56.0%)

 Elevated

1292 (42.6%)

252 (44.0%)

Characteristic

Left-sided

Transverse-sided

P-value

Perineural invasion

0.012^*

 Yes

603 (19.9%)

88 (15.4%)

 No

2432 (80.1%)

485 (84.6%)

Tumor size

 < 0.001^*

 Median (mm)

45.00

50.00

OS month

0.458

 Median

54

54